Samuel Fatoba
About
Samuel Fatoba is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Samuel Fatoba has authored 21 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 9 papers in Internal Medicine and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Samuel Fatoba's work include Venous Thromboembolism Diagnosis and Management (9 papers), Atrial Fibrillation Management and Outcomes (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). Samuel Fatoba is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (9 papers), Atrial Fibrillation Management and Outcomes (7 papers) and Antiplatelet Therapy and Cardiovascular Diseases (3 papers). Samuel Fatoba collaborates with scholars based in United Kingdom, United States and Germany. Samuel Fatoba's co-authors include Jason Oke, Jennifer Hirst, Nathan R. Hill, Daniel Lasserson, Richard Hobbs, Christopher A. O’Callaghan, Andrei L. Okorokov, Gunnar Brobert, Luis A. Garcı́a Rodrı́guez and Luke Roberts and has published in prestigious journals such as Nucleic Acids Research, Blood and PLoS ONE.
In The Last Decade
Samuel Fatoba
18 papers receiving 2.8k citations
Hit Papers
Peers
Samuel Fatoba
Brett Plattner United States
Adrian Covic Romania
James B. Wetmore United States
Chi-Pang Wen Taiwan
Kyu‐Beck Lee South Korea
Chia‐Ter Chao Taiwan
Philip Masson Australia
Amanda H. Anderson United States
Paul E. Drawz United States
Susan T. Crowley United States
Citations per year, relative to Samuel Fatoba Samuel Fatoba (= 1×)
peers
Brett Plattner
Countries citing papers authored by Samuel Fatoba
Since
Specialization
Citations
This map shows the geographic impact of Samuel Fatoba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Fatoba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Fatoba more than expected).
Fields of papers citing papers by Samuel Fatoba
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Samuel Fatoba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Fatoba. The network helps show where Samuel Fatoba may publish in the future.
Co-authorship network of co-authors of Samuel Fatoba
This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Fatoba. A scholar is included among the top collaborators of Samuel Fatoba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Fatoba. Samuel Fatoba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bosworth, Hayden B., Konstantin A. Krychtiuk, John A. Spertus, et al.. (2025). Advancement of the implementation of evidence-based therapies for cardiovascular-kidney-metabolic conditions: A multi-stakeholder perspective. American Heart Journal. 286. 18–34.
2.
Nicholas, Susanne B., Ricardo Correa-Rotter, Nihar R. Desai, et al.. (2024). First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting. Journal of Nephrology. 37(8). 2223–2232.
3.
Vallejo‐Vaz, Antonio J., Kanika Dharmayat, Samuel Fatoba, et al.. (2024). Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: The RESRISK cohort study. Atherosclerosis. 398. 118589–118589.
4.
Tangri, Navdeep, et al.. (2024). Improving the Quality of CKD Care with Risk Prediction and Personalized Recommendations: 1-Year Results from the GEMINI-RAPA Study. Journal of the American Society of Nephrology. 35(10S).
5.
Tangri, Navdeep, Rakesh K. Singh, Keith A. Betts, et al.. (2024). 60-OR: Implementing a Machine-Learning Model to Predict Risk of Chronic Kidney Disease (CKD) Progression. Diabetes. 73(Supplement_1).
6.
Coleman, Craig I, Samuel Fatoba, Marcela Rivera, et al.. (2023). Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism. JACC CardioOncology. 5(2). 189–200.
7.
Whitlock, Reid, Silvia J. Leon, Nicole Askin, et al.. (2023). The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 38(11). 2503–2516.
8.
Nicholas, Susanne B., Kenn B. Daratha, Radica Z. Alicic, et al.. (2023). Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020. Diabetes Obesity and Metabolism. 25(10). 2970–2979.
9.
González‐Pérez, Antonio, Luke Roberts, Pareen Vora, et al.. (2022). Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care. BMJ Open. 12(6). e059311–e059311.
10.
Maraveyas, Anthony, Jan Beyer‐Westendorf, Agnes Y. Lee, et al.. (2021). Cancer‐Associated ThrOmboSIs – Patient‐Reported OutcoMes With RivarOxaban (COSIMO) – Baseline characteristics and clinical outcomes. Research and Practice in Thrombosis and Haemostasis. 5(8). e12604–e12604.
11.
Cohen, Alexander T., Anthony Maraveyas, Jan Beyer‐Westendorf, et al.. (2021). Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism – The COSIMO study. Thrombosis Research. 206. 1–4.
12.
Lee, Agnes Y., Alexander T. Cohen, Anthony Maraveyas, et al.. (2020). Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study). Thrombosis and Haemostasis. 121(2). 206–215.
13.
Rodrı́guez, Luis A. Garcı́a, Mar Martín‐Pérez, Pareen Vora, et al.. (2019). Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK. BMJ Open. 9(9). e031341–e031341.
14.
Ruigómez, Ana, Pareen Vora, Yanina Balabanova, et al.. (2019). Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK. BMJ Open. 9(10). e031342–e031342.
15.
Cohen, Alexander T., Anthony Maraveyas, Jan Beyer‐Westendorf, et al.. (2019). Patient Preferences Regarding Anticoagulation Therapy in Patients with Cancer Having a VTE Event - a Discrete Choice Experiment in the Cosimo Study. Blood. 134(Supplement_1). 2159–2159.
16.
Maraveyas, Anthony, Jan Beyer‐Westendorf, LG Mantovani, et al.. (2019). Baseline Characteristics and Clinical Outcomes from the Cancer Associated Thrombosis - Patient Reported Outcomes with Rivaroxaban (COSIMO) Trial. Blood. 134(Supplement_1). 2161–2161.
17.
Hill, Nathan R., Samuel Fatoba, Jason Oke, et al.. (2016). Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS ONE. 11(7). e0158765–e0158765.
18.
Hill, Nathan R., Daniel Lasserson, Samuel Fatoba, et al.. (2013). The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. BMJ Open. 3(12). e004265–e004265.
19.
Fatoba, Samuel, Silvia Tognetti, Elisabetta Leo, et al.. (2013). Human SIRT1 regulates DNA binding and stability of the Mcm10 DNA replication factor via deacetylation. Nucleic Acids Research. 41(7). 4065–4079.
20.
Fatoba, Samuel & Andrei L. Okorokov. (2011). Human SIRT1 associates with mitotic chromatin and contributes to chromosomal condensation. Cell Cycle. 10(14). 2317–2322.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Brett Plattner Breakdown of academic impact, for papers by Adrian Covic Breakdown of academic impact, for papers by James B. Wetmore Breakdown of academic impact, for papers by Chi-Pang Wen Breakdown of academic impact, for papers by Kyu‐Beck Lee Breakdown of academic impact, for papers by Chia‐Ter Chao Breakdown of academic impact, for papers by Philip Masson Breakdown of academic impact, for papers by Amanda H. Anderson Breakdown of academic impact, for papers by Paul E. Drawz Breakdown of academic impact, for papers by Susan T. Crowley